Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin

Journal of Urology

Volumn 163, Issue 6, 2000, Pages 1697-1701

  Brake, M ^a   Loertzer, H ^a   Horsch, R ^a   Keller, H ^a  

^a Klinikum Offenburg   (Germany)

Author keywords

BCG vaccine; Bladder neoplasms; Carcinoma; Immunotherapy; Transitional cell

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0034096908     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67523-4     Document Type: Article

References (43)

1. Kaubisch, S., Lum, B. L., Reese, J. et al: Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol, 146: 28, 1991
2. Pauwels, R. P., Schapers, R. F., Smeets, A. W. et al: Grading in superficial bladder cancer. (1) Morphological criteria. Br J Urol, 61: 129, 1988
3. Herr, H. W., Jakse, G. and Sheinfeld, J.: The T1 bladder tumor. Semin Urol, 8: 254, 1990
4. Lamm, D. L., Riggs, D. R., Traynelis, C. L. et al: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol, 153: 1444, 1995
5. Boccon-Gibod, L., Leleu, C., Herve, J. M. et al: Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression. Prog Clin Biol Res, 310: 161, 1989
6. Samodai, L., Kiss, L., Kolozsy, Z. et al: The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer. Int Urol Nephrol, 23: 559, 1991
7. Cookson, M. S. and Sarosdy, M. F.: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol, 148: 797, 1992
8. Lamm, D. L.: BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol, suppl., 27: 2, 1995
9. Zhang, G. K., Uke, E. T., Sharer, W. C. et al: Reassessment of conservative management for stage pT1N0M0 transitional cell carcinoma of the bladder. J Urol, 155: 1907, 1996
10. Dal Bo, V., Belmonte, P., Veronesi, A. et al: Intravesical BCG instillations in patients with carcinoma in situ and pT1 G3 transitional cell carcinoma of the bladder. Eur Urol, suppl., 18: 43, 1990
11. Jakse, G., Loidl, W., Seeber, G. et al: Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol, 137: 39, 1987
12. Kälble, T., Köhl, U., Hardt, S. et al: pT1-Blasenkarzinom: Indikation zu transurethralen Elektroresektion oder zur primären radikalen Zystektomie? Akt Urol, 28: 95, 1997
13. Otto, T., Goepel, M., Krege, S. et al: Experimentelle und klinische Untersuchungen zur Biologie des Harnblasenkarzinoms. Akt Urol, 24: 192, 1993
14. Siref, L. E. and Zincke, H.: Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy? Urology, 31: 309, 1988
15. Stöckle, M., Alken, P., Engelmann, U. et al: Radical cystectomy - often too late? Eur Urol, 13: 361, 1987
16. Antelo, M., Dinney, C. P. and Grossman, H. B.: Clinical outcome of T1 bladder cancer. J Urol, suppl., 155: 495A, abstract 736, 1996
17. Eure, G. R., Cundiff, M. R. and Schellhammer, P. F.: Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. J Urol, 147: 376, 1992
18. Gohji, K., Nomi, M., Okamoto, M. et al: Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology, 53: 308, 1999
19. Herr, H. W., Wartinger, D. D., Fair, W. R. et al: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol, 147: 1020, 1992
20. Klän, R., Steiner, U., Sauter, T. et al: Zystektomie beim schlecht differenzierten T1-Harnblasenkarzinom - oft zu früh? Akt Urol, 29: 53, 1998
21. Mulders, P. F., Meyden, A. P., Doesburg, W. H. et al: Prognostic factors in pTa-pT1 superficial bladder tumors treated with intravesical instillations. Br J Urol, 73: 403, 1994
22. Pagano, F., Bassi, P., Milani, C. et al: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol, 146: 32, 1991
23. Pansadoro, V., Emiliozzi, P., Defidio, L. et al: Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol, 154: 2054, 1995
24. Serretta, V., Piazza, S., Pavone, C. et al: Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder. Urology, 47: 647, 1996
25. Malström, P. U., Busch, C. and Norlén, J.: Recurrence, progression and survival in bladder cancer. A retrospective analysis with 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol, 21: 185, 1987
26. Bracken, R. B., McDonald J. and Johnson, D. E.: Cystectomy for superficial bladder cancer. Urology, 18: 459, 1981
27. Malkowicz, S. B., Nichols, P., Lieskovsky, G. et al: The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol, 144: 641, 1990
28. Birch, B. R. P. and Harland, S. J.: The pT1 G3 bladder tumour. Br J Urol, 64: 109, 1989
29. Jenkins, B. J., England, H. R., Fowler, C. G. et al: Chemotherapy for carcinoma in situ of the bladder. Br J Urol, 61: 326, 1988
30. Flamm, J. and Havelec, L.: Factors affecting survival in primary superficial bladder cancer. Eur Urol, 17: 113, 1990
31. Prout, G. R., Jr., Koontz, W. W., Jr., Coombs, L. J. et al: Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol, 130: 677, 1983
32. Slack, N. H., Bross, I. D. and Prout, G. R., Jr.: Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol, 9: 393, 1977
33. Kim, H. H. and Lee, C.: Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. J Urol, 141: 1337, 1989
34. Kurth, K. H., Sylvester, R., de Pauw, M. et al: Intracavitary treatment of transitional cell carcinoma of the bladder: questions and lessons after 27 years of experience. Prog Clin Biol Res, 310: 125, 1989
35. Lamm, D. L. and Griffith, J. G.: Intravesical therapy: does it affect the natural history of superficial bladder cancer? Semin Urol, 10: 39, 1992
36. Bono, A. V., Benvenuti, C., Damiano, G. et al: Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer. Urology, 44: 329, 1994
37. Dalton, J. T., Wientjes, M. G., Badalament, R. A. et al: Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res, 51: 5144, 1991
38. Böhle, A., Thanhäuser, A., Ulmer, A. J. et al: Dissecting the immunobiological effects of Bacillus Calmette-Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol, 150: 1932, 1993
39. Böhle, A. and Jocham, D.: Die intravesikale Immuntherapie mit Bacillus Calmette-Guerin. Fakten, Vergleiche, Ergebnisse. Stuttgart, Jena, Lübeck, Ulm: G. Fischer, 1998
40. Klän, R., Loy, V. and Huland, H.: Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol, 146: 316, 1991
41. Zbar, B., Bernstein, I. D. and Rapp, H. J.: Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guerin. J Natl Cancer Inst, 46: 831, 1971
42. Brosman, S. A.: The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. J Urol, 134: 36, 1985
43. Herr, H. W., Pinsky, C. M., Whitmore, W. F., Jr. et al: Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol, 135: 265, 1986